secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053195
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q1 net loss $26.4M; STK-001 data supports disease modification
--------------------------------------------------------------------------------

- Net loss $26.4M ($0.57/share) vs $22.5M ($0.53) YoY; cash $178.6M at March 31, plus $120.3M net from April follow-on offering.
- STK-001 data from 81 patients showed durable seizure reductions and cognitive/behavior improvements; plans to discuss registrational study with regulators, update H2 2024.
- Revenue from Acadia collaboration $4.2M (down from $5.2M); R&D expenses rose to $22.4M from $19.6M.
- Appointed Jason Hoitt as CCO and Tommy Leggett as CFO.
- Plans to initiate Phase 1 OSPREY trial for STK-002 in ADOA in 2024; FALCON natural history data presented at ARVO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/0000950170-24-053195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/stok-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer